Effects of denosumab on fracture and bone mineral density by level of kidney function
Open Access
- 13 April 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 26 (8), 1829-1835
- https://doi.org/10.1002/jbmr.403
Abstract
The incidences of osteoporosis and chronic kidney disease (CKD) both increase with increasing age, yet there is a paucity of data on treatments for osteoporosis in the setting of impaired kidney function. We examined the efficacy and safety of denosumab (DMAb) among subjects participating in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Study. We estimated creatinine clearance (eGFR) using Cockcroft‐Gault and classified levels of kidney function using the modified National Kidney Foundation classification of CKD. We examined incident fracture rates; changes in bone mineral density (BMD), serum calcium, and creatinine; and the incidence of adverse events after 36 months of follow‐up in subjects receiving DMAb or placebo, stratified by level of kidney function. We used a subgroup interaction term to determine if there were differences in treatment effect by eGFR. Most (93%) women were white, and the mean age was 72.3 ± 5.2 years; 73 women had an eGFR of 15 to 29 mL/min; 2817, between 30 to 59 mL/min; 4069, between 60 to 89 mL/min, and 842 had an eGFR of 90 mL/min or greater. None had stage 5 CKD. Fracture risk reduction and changes in BMD at all sites were in favor of DMAb. The test for treatment by subgroup interaction was not statistically significant, indicating that treatment efficacy did not differ by kidney function. Changes in creatinine and calcium and the incidence of adverse events were similar between groups and did not differ by level of kidney function. It is concluded that DMAb is effective at reducing fracture risk and is not associated with an increase in adverse events among patients with impaired kidney function. © 2011 American Society for Bone and Mineral ResearchKeywords
This publication has 18 references indexed in Scilit:
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2009
- Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone DiseasesJournal of Clinical Densitometry, 2008
- Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairmentOsteoporosis International, 2006
- Relationship between age, renal function and bone mineral density in the US populationOsteoporosis International, 2003
- Osteoclast differentiation and activationNature, 2003
- Editorial boardAmerican Journal of Kidney Diseases, 2002
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAnnals of Internal Medicine, 1999
- Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES IIIJournal of Bone and Mineral Research, 1997
- Prevalence of low femoral bone density in older U.S. women from NHANES IIIJournal of Bone and Mineral Research, 1995
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976